| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net revenue | 1,446,066 | 1,269,483 | ||
| Direct costs and expenses | 942,211 | 1,016,602 | ||
| Research and development | 330,589 | 311,372 | ||
| Clinical development | 143,311 | 129,279 | ||
| Selling, general and administrative | 2,209,441 | 2,214,561 | ||
| Depreciation and amortization | 113,360 | 113,229 | ||
| Total operating expenses | 3,738,912 | 3,785,043 | ||
| Loss from operations | -2,292,846 | -2,515,560 | ||
| Interest income | 1,088 | 2,025 | ||
| Interest expense | 5,358 | 10,460 | ||
| Other income | 513 | 38,053 | ||
| Other expense | 3,839 | 483,043 | ||
| Change in fair value of warrants issued | 2,747,460 | 1,062,818 | ||
| Total other income (expense), net | -2,755,056 | -1,516,243 | ||
| Net loss before provision for income tax expense | -5,047,902 | -4,031,803 | ||
| Provision for income tax expense | 3,182 | 28,984 | ||
| Net loss | -5,051,084 | -4,060,787 | ||
| Net loss per common share, basic | -4.74 | -0.17 | ||
| Net loss per common share, diluted | -4.74 | -0.17 | ||
| Weighted average common shares outstanding, basic | 1,066,350 | 24,021,546 | ||
| Weighted average common shares outstanding, diluted | 1,066,350 | 24,021,546 | ||
bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. (BIAFW)